Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $22.4 million.

  • Pharming's Profit After Tax rose 226982.59% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 6340.73%. This contributed to the annual value of -$11.8 million for FY2024, which is 1225.82% down from last year.
  • As of Q3 2025, Pharming's Profit After Tax stood at $22.4 million, which was up 226982.59% from -$10.3 million recorded in Q2 2025.
  • Pharming's Profit After Tax's 5-year high stood at $22.4 million during Q3 2025, with a 5-year trough of -$14.9 million in Q1 2025.
  • Over the past 5 years, Pharming's median Profit After Tax value was -$677383.1 (recorded in 2021), while the average stood at -$892950.4.
  • Within the past 5 years, the most significant YoY rise in Pharming's Profit After Tax was 4956561.07% (2022), while the steepest drop was 20138.89% (2022).
  • Quarter analysis of 5 years shows Pharming's Profit After Tax stood at $14.4 million in 2021, then plummeted by 201.39% to -$14.6 million in 2022, then rose by 27.75% to -$10.5 million in 2023, then dropped by 4.32% to -$11.0 million in 2024, then skyrocketed by 303.89% to $22.4 million in 2025.
  • Its last three reported values are $22.4 million in Q3 2025, -$10.3 million for Q2 2025, and -$14.9 million during Q1 2025.